Neurochase
Neurochase is a UK privately-held medical-device company that develops and licenses Convection Enhanced Delivery (CED) systems — proprietary micro-catheters and a bone-anchored port — to enable pharmaceutical and biotech partners to deliver gene, cell and conventional therapies across the blood-brain barrier for CNS disorders.
- Company typePrivate
- Founded2020
- HeadquartersBristol, United Kingdom
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Neurochase does
Neurochase Limited is a privately held UK medical-device company, founded in 2020 and headquartered in Cardiff with operational offices in Bristol and Glasgow, that develops and licenses Convection Enhanced Delivery (CED) platforms for targeted delivery of gene, cell and conventional therapies to the central nervous system. Its core product line centres on proprietary CED micro-catheters that use a pressure gradient to drive therapeutics past the blood-brain barrier and distribute them homogeneously through interstitial brain tissue, with cannula insertion achievable within 10 minutes per cannula and reflux control designed for accurate dosing. The platform is complemented by specialised electrospun micro-catheters manufactured in partnership with VIVOLTA using the MediSpin production system, and by the Neuroinfuse drug delivery system — a bone-anchored transcutaneous port acquired from Renishaw Neuro Solutions in November 2025 that enables intermittent, chronic therapy administration over months or years to deep brain targets.
The company monetises through three streams: licensing of its CED drug delivery technology and devices to pharmaceutical and biotech partners for use in their CNS clinical programs, expert consultancy on protocol development, surgical workflow optimisation and surgeon training for both preclinical studies and clinical trials, and future device sales for clinical trial use beginning in 2025. Its customer base consists of pharma and biotech sponsors developing gene and cell therapies for Parkinson's, Huntington's, MND/ALS, drug-resistant epilepsy, brain tumours and dementia, plus supporting CROs; named partners include Spark Therapeutics (Roche), CombiGene, Innervate Therapeutics, Hamlet Pharma and AviadoBio.
Neurochase is led by Founder and CSO Prof. Steven Gill, a pioneer of deep brain stimulation and the first clinical trial infusing GDNF directly into the brain, alongside CEO Sharon Kane, Medical Director Neil Barua and Chief Marketing Officer Jacqueline Keller. The company cites over 5,000 catheter infusions delivered to humans, a Phase 2 Parkinson's trial demonstrating neuro-restoration, and doubled progression-free survival in DIPG brainstem cancer as evidence of clinical credibility supporting its £1.5B addressable market claim for CNS drug delivery.
Neurochase firmographics
Firmographics- Name
- Neurochase
- Legal name
- Neurochase Limited
- Website
- https://neurochase.com
- Company type
- Private
- Founded year
- 2020
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Neurochase is a UK privately-held medical-device company that develops and licenses Convection Enhanced Delivery (CED) systems — proprietary micro-catheters and a bone-anchored port — to enable pharmaceutical and biotech partners to deliver gene, cell and conventional therapies across the blood-brain barrier for CNS disorders.
- Ownership category
- akta.pro rank
Neurochase industry classification
Industry- Product category
- CNS Drug Delivery Medical Devices
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Surgical and Medical Instrument Manufacturing (339112)
- SIC
- Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Neurology & Psychiatry (CNS) Pharmaceuticals (HLAIAAAF)
Keywords
Where Neurochase is headquartered
LocationHeadquarters
- HQ city
- Bristol
- HQ country
- United Kingdom
- HQ region
- Europe
Offices3 records
Markets served
Neurochase business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales
Revenue model
- Drug Delivery Device Licensing: Neurochase licenses its proprietary CED drug delivery technology and devices to pharmaceutical and biotech companies for use in their clinical programs. The company provides access to its technology platform including micro-catheters and delivery systems.
- Consultancy Services: Expert consultancy to biotech and pharma on direct delivery of therapies to the CNS. Services include protocol development, surgical workflow optimisation, and surgeon training. Pre-clinical support includes stereotactic equipment, devices and training to CROs.
- Device Sales: Sale and supply of CED drug delivery devices for clinical trials. From 2025, access to CED devices for clinical trial use. The company planned clinical trial for early 2026 using Neuroinfuse system.
Go-to-market motion2 records
Distribution channels1 record
Marketing channels4 records
Neurochase product offering
Product offeringCore offering
Neurochase develops and licenses proprietary Convection Enhanced Delivery (CED) technology for targeted intraparenchymal drug delivery to the central nervous system. Its flagship platform uses micro-catheters with pressure gradient-driven convection to push therapeutics through interstitial space, enabling homogeneous distribution past the blood-brain barrier directly to specific brain targets. The company licenses its CED system and acquired Neuroinfuse drug delivery platform to pharmaceutical and biotech partners, and provides accompanying consultancy, preclinical support, and clinical trial services.
Product overview
Neurochase offers a unified platform for targeted CNS drug delivery combining proprietary and acquired technologies. The core offering consists of the Neurochase CED Drug Delivery System - a scalable convection-enhanced delivery platform - integrated with the acquired Neuroinfuse™ system (bone-anchored transcutaneous port for chronic delivery) and specialized electrospun micro-catheters manufactured via VIVOLTA partnership. Supporting the technology portfolio are consultancy and training services for pre-clinical studies, clinical trials, and ongoing CNS drug delivery projects. The combined portfolio addresses both acute and chronic delivery needs across conditions including Parkinson's Disease, Huntington's Disease, brain tumors, and MND.
Differentiator
Problem solved
Functional benefit
Products and services
- Neurochase CED Drug Delivery System
Quantifiable outcome
- More than 5,000 catheter infusions delivered to humans
- +3 more outcomes
Companies that use Neurochase
Customer profileNamed customers5 records
Segments2 records
Ideal customer profiles2 records
Neurochase technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Neurochase partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered flagship and core.
- Renishaw Neuro SolutionsflagshipAcquisition of Renishaw Neuro Solutions’ key strategic device assets including the Neuroinfuse drug delivery system and all associated IP. The Neuroinfuse system comprises bone-anchored transcutaneous port for intermittent therapy administration over months or years. Deal creates premier global platform for targeted CNS drug delivery.
- VIVOLTAcoreLong-term manufacturing partnership where VIVOLTA serves as exclusive electrospun component manufacturer for Neurochase’s micro-catheter delivery system. VIVOLTA first partnered with Neurochase in 2022 for product development and has been part of R&D team bringing material science expertise. VIVOLTA’s fully-automated MediSpin production system enables scalable manufacturing.
- Hamlet PharmacoreJoint development agreement to develop novel technology and methods to treat CNS tumors with Alpha1H. Collaboration involves developing new technology for delivery of Alpha1H to the leptomeninges for treatment of primary and secondary CNS tumors including glioblastomas. Primarily explores infusion in preclinical models.
- Spark Therapeutics (Roche Group)flagshipStrategic collaboration to develop Neurochase’s proprietary delivery technology for use with selected gene therapies for rare diseases in CNS. Neurochase brings deep expertise in direct drug delivery technology to Spark’s leading AAV platform. Collaboration aims to improve targeted delivery of AAV gene therapy to neural structures using CED for diseases like Huntington’s Disease.
- CombiGenecorePreclinical study partnership to optimize administration of CG01 (gene therapy for drug-resistant focal epilepsy) using Neurochase injection device. Study evaluated injection volume and rate, providing valuable information for upcoming toxicology and biodistribution studies. CombiGene has exclusive collaboration and licensing agreement for CG01 with Spark Therapeutics.
- Innervate TherapeuticscoreExclusive license agreement for use of Neurochase devices and technology for GDNF gene therapy delivery. Innervate is developing GDNF gene therapies for Parkinson’s Disease and Motor Neuron Disease (MND/ALS). Neurochase’s technology enables scaling delivery and safe administration to large patient populations.
Scale indicators4 records
Recent moves6 records
Expansion highlights5 records
Neurochase competitors and assessment
Company assessmentDirect peers
- ClearPoint Neuro: ClearPoint Neuro provides MRI-guided intraparenchymal drug delivery systems for the CNS and is the closest direct competitor to Neurochase's CED platform; Neurochase's incoming CMO Jacqueline Keller was previously VP Marketing at ClearPoint Neuro, underscoring direct comparability.
Others
- Renishaw Neuro Solutions: Former division of Renishaw plc whose Neuroinfuse drug delivery assets Neurochase acquired in November 2025; historically a direct peer in CED/catheter-based CNS delivery and now a transferor of IP rather than an active competitor.
- Spark Therapeutics (Roche): Spark Therapeutics (a Roche company) develops AAV gene therapies for CNS diseases and is Neurochase's flagship collaboration partner; comparable as an ecosystem participant that both consumes delivery platforms and validates demand for CED.
- uniQure: uniQure develops AAV-based gene therapies for CNS disorders (e.g., Huntington's) and represents a comparable ecosystem participant that would require targeted CNS delivery solutions like Neurochase's CED platform.
- Voyager Therapeutics: Voyager Therapeutics develops AAV gene therapies for severe neurological diseases (Parkinson's, ALS, Huntington's) and is a comparable ecosystem participant needing advanced CNS delivery capabilities similar to those Neurochase offers.
- AivadoBio: AviadoBio develops AAV gene therapies for frontotemporal dementia and ALS and collaborates with Neurochase (Prof. Gill on its SAB); an emerging gene therapy peer that represents both a customer and a comparable technology ecosystem participant.
Broad incumbents
- Brainlab: Brainlab offers broad neurosurgical navigation, planning, and surgical robotics used in stereotactic drug delivery procedures; comparable as a broader incumbent enabling the same surgical workflows Neurochase supports.
- Medtronic: Medtronic operates drug delivery infusion systems (e.g., SynchroMed for intrathecal therapy) and deep brain stimulation infrastructure; a broad incumbent with overlapping CNS delivery/catheter capabilities, though not focused on CED intraparenchymal delivery.
- Integra LifeSciences: Integra LifeSciences supplies a portfolio of neurosurgical instruments, catheters, and implantable devices used in CNS procedures, including components comparable to Neurochase's stereotactic and catheter workflow.
- Abbott Neuromodulation: Abbott's neuromodulation business (formerly St. Jude) provides implantable neurostimulation devices including DBS, sharing the same neurosurgical implantation ecosystem and competing for hospital neurosurgery budgets alongside Neurochase's CED platform.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Neurochase social profiles
Digital presenceNeurochase financial estimates
Financial estimateRevenue estimate
Valuation estimate
Neurochase leadership team
Management profileNumber of profiles
Profiles5 records
Neurochase funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Neurochase M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Neurochase
What does Neurochase do?
Neurochase develops and licenses proprietary Convection Enhanced Delivery (CED) technology for targeted intraparenchymal drug delivery to the central nervous system. Its flagship platform uses micro-catheters with pressure gradient-driven convection to push therapeutics through interstitial space, enabling homogeneous distribution past the blood-brain barrier directly to specific brain targets. The company licenses its CED system and acquired Neuroinfuse drug delivery platform to pharmaceutical and biotech partners, and provides accompanying consultancy, preclinical support, and clinical trial services.
Is Neurochase a public or private company?
Neurochase is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Neurochase founded?
Neurochase was founded in 2020. It employs 11 to 50 people.
Where is Neurochase based?
Neurochase is headquartered in Bristol, United Kingdom, in the Europe region.
How does Neurochase make money?
Three revenue lines are on record. Drug Delivery Device Licensing is the primary driver. The others are consultancy Services and device Sales.
Who are Neurochase's main competitors?
ClearPoint Neuro is listed as a direct peer. Others are Renishaw Neuro Solutions, Spark Therapeutics (Roche), uniQure, Voyager Therapeutics and AivadoBio. Broad incumbents are Brainlab, Medtronic, Integra LifeSciences and Abbott Neuromodulation.
Does Neurochase have an API?
No public API is recorded for Neurochase.
What industry is Neurochase in?
Neurochase's product category is CNS Drug Delivery Medical Devices. Its primary akta.pro industry code is HLAIAAAF, Neurology & Psychiatry (CNS) Pharmaceuticals. Its NAICS code is 334510 and its SIC code is 3845.